All Posts Tagged With: "FACT"
(ABT) Abbott a Step Closer to in Aquisition Facet Biotech
Abbott (ABT) recently announced the expiry of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 (HSR) for its cash tender offer for Facet Biotech Corporation’s (FACT) outstanding shares. Abbott had announced its plans to acquire Facet earlier...
9Apr2010 | vitalstocks | 0 comments | Continued(ABT) Abbott Labs Completes Starlims Buyout
Abbott Labs (ABT) recently completed the acquisition of Starlims Technologies Ltd. for $123 million. Starlims is a leading provider of laboratory information management systems. It improves the reliability of laboratory sampling processes, supports compliance with domestic and...
25Mar2010 | vitalstocks | 0 comments | Continued(TRBN) Trubion Pharmaceuticals’ Loss is Wider Than Expected
Trubion Pharmaceuticals, Inc.’s (TRBN) fourth quarter fiscal 2009 net loss per share came in at 29 cents, wider than the Zacks Consensus Estimate by 10 cents. The year-ago loss was 36 cents. The year-over-year decline in loss for the reported quarter was attributable to higher...
23Mar2010 | vitalstocks | 0 comments | Continued(ABT) Abbott Laboratories on an Acquisition Spree
Abbott (ABT) continues to be in an acquisition mode, recently announcing its intention to acquire Facet Biotech Corporation (FACT) for $27 per share. The total purchase price is approximately $722 million Incorporatedluding Facet’s projected cash and marketable securities of...
10Mar2010 | vitalstocks | 0 comments | Continued(FACT) Facet Biotech Rejects Biogen Idec Again
Facet Biotech Corp. (FACT) once again rejected Biogen Idec Inc.’s (BIIB) intention to acquire all the outstanding shares of Facet common stock stating that the revised offer is inadequate and not in the best interests of Facet Biotech’s stockholders. Earlier this month,...
11Dec2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Reports Higher Earnings
Today morning, Biogen Idec (BIIB) reported third quarter earnings per share of $1.12, beating the Zacks Consensus Estimate of $1.02. The company reported earnings of 98 cents in the year-ago period. Revenues increased 3% to $1.12 billion, with Tysabri being the primary growth...
20Oct2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Extends Hostile Bid For Facet Biotech Corporation
Biogen Idec Inc. (BIIB) extended its tender offer for the acquisition of all of the outstanding shares of Facet Biotech Corporation (FACT) to December 16, 2009. The offer was previously set to expire on October 19, 2009. As of October 15, 2009, about 28,336 shares of Facet Biotech...
20Oct2009 | vitalstocks | 0 comments | Continued(FACT) Facet Investors Urged to Deny Biogen Idec Tender Offer
In line with expectations, Facet Biotech Corporation’s (FACT) board of directors unanimously recommended that its stockholders should reject the unsolicited conditional tender offer from Biogen Idec Inc. (BIIB), which is seeking to acquire all the outstanding shares of Facet...
12Oct2009 | vitalstocks | 0 comments | Continued(BIIB) Biogen Launches Hostile Bid for Partner Facet Biotech
After being refused twice, Biogen Idec (BIIB) launched a hostile bid to acquire its development partner, Facet Biotech (FACT) for $14.50 per share, by taking its offer directly to Facet’s shareholders. Biogen also sent a letter to Facet’s Board stating that Facet’s cash...
24Sep2009 | vitalstocks | 0 comments | Continued